Cargando…
Change in renal function associated with drug treatment in heart failure: national guidance
Inhibitors of the renin–angiotensin–aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF). However, RAAS inhibitors may cause decline in renal function and/or hyperkalaemia, particularly during initiation a...
Autores principales: | Clark, Andrew L, Kalra, Paul R, Petrie, Mark C, Mark, Patrick B, Tomlinson, Laurie A, Tomson, Charles RV |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582720/ https://www.ncbi.nlm.nih.gov/pubmed/31118203 http://dx.doi.org/10.1136/heartjnl-2018-314158 |
Ejemplares similares
-
Characteristics and outcomes of patients with suspected heart failure referred in line with National Institute for Health and Care Excellence guidance
por: Zheng, Alice, et al.
Publicado: (2020) -
Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018) -
Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials
por: Graham, Fraser J., et al.
Publicado: (2021) -
Association of chronic kidney disease (CKD) and failure to monitor renal function with adverse outcomes in people with diabetes: a primary care cohort study
por: McGovern, Andrew P, et al.
Publicado: (2013) -
Talking to patients with heart failure about end of life
por: Campbell, Ross T., et al.
Publicado: (2018)